Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Lipoma | Case report

Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas: case report

Authors: Yoshiro Fushimi, Shinji Kamei, Fuminori Tatsumi, Junpei Sanada, Masashi Shimoda, Tomohiko Kimura, Atsushi Obata, Shuhei Nakanishi, Kohei Kaku, Tomoatsu Mune, Hideaki Kaneto

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Multiple endocrine
neoplasia type 1 (MEN1) is a syndrome characterized by pituitary neoplasia, primary hyperparathyroidism and pancreatic endocrine tumor. Here we show a case of MEN1 with a germline frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas.

Case presentation

A 28-year-old man noticed the decreased visual acuity of both eyes and visited our institution. Since he was diagnosed as visual disturbance and brain computer tomography (CT) showed a mass in the pituitary fossa, he was hospitalized in our institution. Endoscopic trans-sphenoidal hypophysectomy and total parathyroidectomy with auto-transplantation were performed, and a giant cervical lipoma was resected. Furthermore, in genetic search, we found a germline frameshift mutation in MEN1 gene leading to the appearance of a new stop codon.

Conclusions

We should bear in m
ind that giant skin lipoma and multiple abnormal fatty deposits in the pancreas could be complicated with MEN1.
Literature
1.
go back to reference Piecha G, Chudek J, Wiecek A. Multiple Endocrine Neoplasia type 1. Eur J Intern Med. 2008;19:99–103.CrossRef Piecha G, Chudek J, Wiecek A. Multiple Endocrine Neoplasia type 1. Eur J Intern Med. 2008;19:99–103.CrossRef
2.
go back to reference Powell AC, Libutti SK. Multiple endocrine neoplasia type 1: clinical manifestations and management. Cancer Treat Res. 2010;153:287–302.CrossRef Powell AC, Libutti SK. Multiple endocrine neoplasia type 1: clinical manifestations and management. Cancer Treat Res. 2010;153:287–302.CrossRef
3.
go back to reference Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, Brandi ML. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009;11:825–35.CrossRef Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T, Brandi ML. Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009;11:825–35.CrossRef
4.
go back to reference Zhou Y, Zhang X, Klibanski A. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol. 2014;386:16–33.CrossRef Zhou Y, Zhang X, Klibanski A. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol. 2014;386:16–33.CrossRef
5.
go back to reference Lecoq AL, Kamenicky P, Guiochon-Mantel A, Chanson P. Genetic mutations in sporadic pituitary adenomas-what to screen for? Nat Rev Endocrinol. 2014;11:43–54.CrossRef Lecoq AL, Kamenicky P, Guiochon-Mantel A, Chanson P. Genetic mutations in sporadic pituitary adenomas-what to screen for? Nat Rev Endocrinol. 2014;11:43–54.CrossRef
6.
go back to reference Hai N, Aoki N, Matsuda A, Mori T, Kosugi S. Germline MEN1 mutations in sixteen Japanese families with multiple endocrine neoplasia type 1 (MEN1). Eur J Endocrinol. 1999;141:475–80.CrossRef Hai N, Aoki N, Matsuda A, Mori T, Kosugi S. Germline MEN1 mutations in sixteen Japanese families with multiple endocrine neoplasia type 1 (MEN1). Eur J Endocrinol. 1999;141:475–80.CrossRef
7.
go back to reference Sturialea A, Giudici F, Alemannoa G, Cavalli T, Addasi R, Santomaggio C, Meoni G, Brandi ML, Tonelli F. Massive intrathoracic lipoma in men1 syndrome. International Journal of Surgery Case Reports. 2015;6(247–250):2015. Sturialea A, Giudici F, Alemannoa G, Cavalli T, Addasi R, Santomaggio C, Meoni G, Brandi ML, Tonelli F. Massive intrathoracic lipoma in men1 syndrome. International Journal of Surgery Case Reports. 2015;6(247–250):2015.
8.
go back to reference Iyer S, Agarwal SK. Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types. J Mol Endocrinol. 2018;61:13–24.CrossRef Iyer S, Agarwal SK. Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types. J Mol Endocrinol. 2018;61:13–24.CrossRef
9.
go back to reference Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab. 2014;99:E2387–91.CrossRef Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab. 2014;99:E2387–91.CrossRef
Metadata
Title
Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas: case report
Authors
Yoshiro Fushimi
Shinji Kamei
Fuminori Tatsumi
Junpei Sanada
Masashi Shimoda
Tomohiko Kimura
Atsushi Obata
Shuhei Nakanishi
Kohei Kaku
Tomoatsu Mune
Hideaki Kaneto
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00821-7

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine